Top Growth Trends in the Benign Prostatic Hyperplasia Treatment Market: Key Insights and Opportunities for 2025-2034
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What key factors are powering the surge in the benign prostatic hyperplasia treatment market right now?
The market size for benign prostatic hyperplasia treatment has seen a robust expansion over the past few years. The market is projected to swell from a worth of $8.23 billion in 2024 to an estimated $8.71 billion in 2025, signifying a compound annual growth rate (CAGR) of about 5.9%. The historical growth of the market has been influenced by factors like increased awareness and screening initiatives, heightened occurrence of BPH, a rise in healthcare cognizance, enhancements in healthcare facilities, and a burgeoning elderly demographic.
How fast Is the benign prostatic hyperplasia treatment market expected to grow, and what’s its future value?
The market for benign prostatic hyperplasia treatment is anticipated to experience significant expansion over the next years, with a prediction to surge to $10.83 billion in 2029, progressing at a compound annual growth rate of 5.6%. Several factors are responsible for the estimated growth in this time frame, including the increasing uptake of minimally invasive procedures, a rising number of older patients, enhanced accessibility to sophisticated treatment choices, more emphasis on patient-focused care, and increased incidence of comorbidities. Prominent trends projected during this period encompass the development of targeted therapies, the incorporation of digital health strategies, advances in surgical procedures, the use of 3D imaging for diagnosis, and innovation in models of care centered on the patient.
Get your benign prostatic hyperplasia treatment market report here!
What are the leading drivers of growth in the benign prostatic hyperplasia treatment market?
The benign prostatic hyperplasia treatment market is projected to see substantial growth, spurred on by an increase in the uptake of minimally invasive surgeries. Such surgeries entail the use of minor or even no incisions, harnessed in conjunction with specialized tools to diminish pain, recovery time, and the possibility of complications. The accelerating prevalence of these surgeries can be attributed to their myriad advantages including reduced pain, prompt recovery time, decreased likelihood of complications, and superior aesthetic outcomes. Utilizing these minimally invasive approaches in the treatment of benign prostatic hyperplasia can yield benefits such as decreased recovery time, lower complication risks, and effective symptom alleviation, thereby improving the overall results of the surgery. For instance, global records from September 2023 show that the American Society of Plastic Surgeons (ASPS), a professional association based in the United States, reported 23,672,269 cosmetic minimally invasive procedures performed worldwide in 2022, with treatments including neuromodulator injections, lip augmentation, and non-surgical skin tightening. Consequently, this growing implementation of minimally invasive surgeries is fuelling the growth of the benign prostatic hyperplasia treatment market.
What are the key segments defining the benign prostatic hyperplasia treatment market?
The benign prostatic hyperplasia treatment market covered in this report is segmented –
1) By Treatment: Minimal Invasive Surgery, Invasive Surgery
2) By Therapeutic Class: Alpha Blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Other Therapeutic classes
3) By End User: Home Healthcare, Hospitals And Clinics, Research And Manufacturing
Subsegments:
1) By Minimal Invasive Surgery: Transurethral Resection of the Prostate (TURP), Laser Surgery, Prostatic Urethral Lift, Transurethral Incision of the Prostate (TUIP), Microwave Therapy
2) By Invasive Surgery: Open Prostatectomy, Robotic Prostatectomy
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21112&type=smp
Who are the key players steering the development of the benign prostatic hyperplasia treatment market?
Major companies operating in the benign prostatic hyperplasia treatment market are Pfizer Inc., Merck And Co Inc, AbbVie Inc., Bayer AG, Sanofi S.A., GlaxoSmithKline Public Limited Company, Medtronic Public Limited Company, Mezzion Pharma Co Ltd, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Boston Scientific Corporation, Astellas Pharma Inc., Olympus Corporation, Coloplast Group, Teleflex Incorporated, Cook Medical Incorporated, AngioDynamics, Inc., HistoSonics Inc, Urovant Sciences Ltd, UroGen Pharma Ltd., Urologix Inc, Zenflow Inc, Butterfly Medical Ltd.
What are the key trends shaping the future of the benign prostatic hyperplasia treatment market?
Significant firms in the benign prostatic hyperplasia treatment sector are giving precedence to the advancement of novel solutions such as minimally invasive methods to improve patient results and reduce recovery durations. These techniques require tiny or no cuts, consequently reducing trauma, pain, and possible issues, as they offer a quicker recovery over conventional surgeries. For example, Teleflex Incorporated, a medical device organization based in the United States, introduced the UroLift System for managing benign prostatic hyperplasia in December 2022. This system uses small permanent implants to adjust the enlarged prostate tissue position, providing substantial symptom relief without requiring tissue removal, cutting, or heating. As an outpatient procedure, it enables swift recovery and the preservation of sexual function. It also ensures superior symptom relief compared to typical BPH medicines, with side effects generally settling within two to four weeks.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21112
Which regions are most influential in expanding the benign prostatic hyperplasia treatment market?
North America was the largest region in the benign prostatic hyperplasia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the benign prostatic hyperplasia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Anti-Cancer MAbS Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/anti-cancer-mabs-global-market-report
Antispasmodics Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/antispasmodics-drugs-global-market-report
Large Volume Parenteral LVP Global Market Report 2025
https://thebusinessresearchcompany.com/report/influenza-vaccines-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
